rheumatoid arthritis

Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Biopharma Dive
Gilead Sciences
Galapagos
JAK inhibitors
rheumatoid arthritis
filgotinib
Flag link:
Generic arthritis drug comes up short against inflammation in heart disease
Generic arthritis drug comes up short against inflammation in heart disease
Stat
generics
rheumatoid arthritis
methotrexate
Flag link:
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Fierce Biotech
JNJ
OSE Immuotherapeutics
FR104
autoimmune disease
rheumatoid arthritis
Flag link:
AbbVie rheumatoid arthritis drug succeeds in late stage trial
AbbVie rheumatoid arthritis drug succeeds in late stage trial
Yahoo/Reuters
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
Flag link:
GlaxoSmithKline’s rheumatoid arthritis prospect misses phase 2 endpoint
GlaxoSmithKline’s rheumatoid arthritis prospect misses phase 2 endpoint
Fierce Pharma
GSK
rheumatoid arthritis
GSK3196165
clinical trials
Flag link:
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
Yahoo/Motley Fool
AbbVie
Gilead Sciences
FDA
rheumatoid arthritis
Upadacitinib
filgotinib
Flag link:
Galapagos shares surge on RA drug trial results
Galapagos shares surge on RA drug trial results
Pharmaforum
Gilead Sciences
Galapagos
filgotinib
rheumatoid arthritis
clinical tgrials
Flag link:
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Fierce Biotech
Gilead Sciences
JAK inhibitors
filgotinib
rheumatoid arthritis
Flag link:
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Yahoo/Zacks.com
Amgen
ABP 710
JNJ
Merck
Remicade
biosimilars
rheumatoid arthritis
Flag link:
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
Yahoo/Motley Fool
AbbVie
Huimra
Upadacitinib
rheumatoid arthritis
Flag link:
AbbVie to submit upadacitinib to FDA after 5th trial win
AbbVie to submit upadacitinib to FDA after 5th trial win
Fierce Pharma
AbbVie
Upadacitinib
rheumatoid arthritis
FDA
JAK inhibitors
Flag link:
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Xconomy
Eli Lilly
Incyte
FDA
rheumatoid arthritis
olumiant
baricitinib
Flag link:
Gilead and Alphabet's Verily to Collaborate on Research in Immunological and Molecular Drivers of Inflammatory Diseases
Gilead and Alphabet's Verily to Collaborate on Research in Immunological and Molecular Drivers of Inflammatory Diseases
CP Wire
Gilead Sciences
Verily
Immunoscape
lupus
rheumatoid arthritis
inflammatory bowel disease
Flag link:
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
CP Wire
AbbVie
rheumatoid arthritis
Upadacitinib
clinical trials
Flag link:
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
Xconomy
Eli Lilly
FDA
advisory panels
rheumatoid arthritis
baricitinib
Incyte
Flag link:
Big Week Ahead for Eli Lilly: Here's What to Look For
Big Week Ahead for Eli Lilly: Here's What to Look For
Motley Fool
Eli Lilly
earnings
FDA
Incyte
olumiant
rheumatoid arthritis
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Incyte
TG Therapeutics
Cara Therapeutics
CR845
opioids
ublituximab
leukemia
olumiant
rheumatoid arthritis
Flag link:
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms
Xconomy
Eli Lilly
baricitinib
olumiant
rheumatoid arthritis
Flag link:
With study success, AbbVie's arthritis hopeful looks to be a safer bet
With study success, AbbVie's arthritis hopeful looks to be a safer bet
Biopharma Dive
AbbVie
rheumatoid arthritis
Upadacitinib
Humira
clinical trials
Flag link:
Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment
Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment
Fierce Biotech
Alivio Therapeutics
hydrogels
rheumatoid arthritis
Flag link:

Pages